

1 **Title:** Usage and awareness of antiviral medications for COVID-19

2

3 **Authors:** Kojima N¹ and Klausner JD²

4

5 ¹ Department of Medicine, University of California Los Angeles, Los Angeles, 90095

6 ² Department of Population and Public Health Sciences, University of Southern

7 California, Keck School of Medicine, Los Angeles, 90033

8

9 **Keywords:** COVID-19; SARS-CoV-2; Antiviral

10

11

12

13

14

15

16

17

18

19

20

21 **Corresponding Author Contact Information:**

22 Department of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA

23 90095. Email: nkojima@ucla.edu

24

25 Abstract

26 We surveyed people that recently tested positive for SARS-CoV-2 to assess the
27 frequency and correlates of early treatment seeking behavior. Among high risk
28 respondents, 66.0% were aware of treatment for COVID-19 and 36.3% had sought
29 treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection.
30 More public outreach is needed to raise awareness of the benefits of treatment for
31 COVID-19.

32

33 Main Text

34 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
35 coronavirus 2 (SARS-CoV-2), continues to cause severe disease, hospitalization, and
36 death. There are effective means to treat SARS-CoV-2 infection [1-4], however is it not
37 clear how often those who would benefit most use monoclonal antibodies, molnupiavir,
38 and nirmatrelvir. We surveyed users of a national SARS-CoV-2 testing company to
39 assess treatment awareness, treatment seeking behavior, and use of antiviral
40 medications for those with a positive test result.

41
42 We recruited adults (18 years or older) who had tested positive for SARS-CoV-2 by a
43 reverse transcriptase polymerase chain reaction (RT-PCR) assay at a large clinical
44 laboratory (Curative, San Dimas, CA). To be eligible, individuals had to have a positive
45 RT-PCR test result within 7 days of enrollment. All surveys were anonymous and
46 voluntary. We collected data on age, assess treatment awareness, treatment seeking
47 behavior, and use of antiviral medications for COVID-19. Descriptive statistics were
48 calculated on StataSE (StataCorp, College Station, TX). Advarra deemed the study IRB
49 exempt (Pro00059961).

50
51 There were 1,159 respondents during March 2022. Among individuals aged 65 years
52 and older, 66.0% were aware of treatment for COVID-19 and 36.3% had sought
53 treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection
54 (Figure). Rates were similar among younger individuals.

55

56 Due to the timing of the survey, infections were most likely caused by either the
57 Omicron variant of SARS-CoV-2 or a sublineage of the Omicron variant, which might be
58 less severe in those with prior immunity [5]. Our findings demonstrate that increased
59 awareness and use of antivirals among those at risk for severe disease due to COVID-
60 19 are urgently needed among individuals that test positive for SARS-CoV-2.

61

62 Declarations

63 Declaration of competing interests

64 NK is a consultant for Curative. JDK is an independent consultant and serves as the
65 Medical Director of Curative.

66

67 Funding

68 Curative Inc. and by a gift to the Keck School of Medicine of the University of Southern
69 California by the W.M. Keck Foundation.

70

71 Acknowledgements

72 To the participants that donated their time.


73

74 References

- 75 1. O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV
76 Antibody Combination to Prevent Covid-19. N Engl J Med **2021**; 385(13): 1184-
77 95.
- 78 2. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with
79 SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med **2021**; 385(21):
80 1941-50.
- 81 3. Whitley R. Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-
82 19. N Engl J Med **2021**.
- 83 4. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment
84 with fluvoxamine on risk of emergency care and hospitalisation among patients
85 with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob
86 Health **2022**; 10(1): e42-e51.
- 87 5. Christie B. Covid-19: Early studies give hope omicron is milder than other
88 variants. BMJ **2021**; 375: n3144.
- 89 6. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of
90 serious illness, company reports. BMJ **2021**; 375: n2713.

91

92 Figure. Treatment awareness, treatment seeking behavior, and use of antiviral medications among individuals 65 years
93 and older versus individuals younger than 65 years that tested positive for SARS-CoV-2 infection in 37 States in the
94 United States from 1 March 2021 to 30 March 2021



95

96